ResearcherUniversity of North Carolina at Chapel HillNo recent work listed

Meagan B. Ryan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0009-0002-1699-3986; OpenAlex author ID A5065734287; NIH RePORTER profile ID 11697650. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 1
Labs led: 0
Collaborators: 19

Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 grant · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 2

Grants 1

Defining the role of ERK1 and ERK2 in Pancreatic Cancer F31CA192829 ↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jonathan M. DeLiberty · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Kristina Drizyte‐Miller · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Bjoern Papke · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Ye S. Lee · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Emanuel F. Petricoin · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
J. Nathaniel Diehl · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Calvin Jay Kuo · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Mariaelena Pierobon · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Kirsten L. Bryant · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Adrienne D. Cox · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Jennifer E. Klomp · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Christopher M Counter · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Clint A. Stalnecker · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Andrew M. Waters · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Channing J. Der · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Craig M. Goodwin · 1 shared paper, 2021 · strength 0.09
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060 ↗
Deepali Bang · 1 shared paper, 2013 · strength 0.05
- Paper GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical … DOI 10.1158/2159-8290.cd-12-0541 ↗
Jen Jen Yeh · 1 shared paper, 2013 · strength 0.05
- Paper GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical … DOI 10.1158/2159-8290.cd-12-0541 ↗
ALBERT Sidney BALDWIN · 1 shared paper, 2013 · strength 0.05
- Paper GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical … DOI 10.1158/2159-8290.cd-12-0541 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.